First Trust Advisors LP Genprex, Inc. Transaction History

First Trust Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.59 - $3.36 $280,310 - $363,646	-108,228 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.87 $11,500 - $18,009	-3,698 Reduced 3.3%	108,228 $363,000
Q1 2021 May 14, 2021	BUY	$3.66 - $7.67 $93,908 - $196,796	25,658 Added 29.74%	111,926 $482,000
Q4 2020 Feb 02, 2021	SELL	$3.03 - $5.51 $6,656 - $12,105	-2,197 Reduced 2.48%	86,268 $358,000
Q3 2020 Nov 05, 2020	BUY	$2.9 - $4.29 $256,548 - $379,514	88,465 New	88,465 $297,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $64.3M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.